Faron Pharmaceuticals Oy (LSE:FARN) - Share price


Stock Report

Faron Pharmaceuticals Oy FARN

Last Price
GBX450.00

Day Change
37.50|9.09%

As of 17/09/2021
16:35:08 BST | GBX
Minimum 15 Minutes Delay.

Last Close412.50p
Day Range425.00 - 455.00
Mkt Cap227.10Mil
52-Wk Range216.05 - 495.00
Yield %-
ISINFI4000153309
Volume45,966
P/E-
P/SInfinity
P/CF-11.78

Share Price

Total Returns 17/09/2021

 Chg (%)  
More ...
Faron Pharmaceuticals Oy0.56 
FTSE 100 TR GBP-2.51
 
Financials
201820192020
More ...
Income Statement
Turnover0.020.000.00
Operating Profit-19.65-13.10-16.65
Net Profit-20.09-13.26-16.95
Reported EPS-0.65-0.36-0.37
Balance Sheet
Current Assets6.839.207.37
Non Current Assets1.181.011.00
Total Assets8.0010.218.37
Current Liabilities5.756.086.50
Total Liabilities---
Total Equity0.371.61-1.85
Cash Flow
Operating Cash Flow-20.52-11.51-17.48
Net Change in Cash-5.282.99-2.83
Director Dealings
TradedActionNotifierPriceAmountValue
More ...
07/04/2021Exercise of OptionMr. Toni Hanninen1.0940,00043,600.00

Company Profile

Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company developing novel treatments for medical conditions with unmet needs. The company has a pipeline based on the receptors involved in the regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy in phase I/II development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Traumakine, the company's investigational intravenous interferon beta-1a is an anti-viral and anti-inflammatory agent, being tested in several Phase III studies around the world against COVID-19.

Sector

Biotechnology

Index

FTSE AIM All-Share

Next Event 25/03/2022

Final Results
Ratios
Comp
More ...
PER (E)0.00
Div Yld (E)0.00
PEG (E)0.00
ROCE-900.59
Op Mrgn0.00
EPS Grwth0.00
Dividends
PreviousLatest
More ...
Record Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00
Directors
More ...
Non-Executive DirectorDr. Gregory B. Brown,M.D.
Non-Executive Director, ChairmanDr. Frank Murdoch Armstrong
Non-Executive Director, Vice ChairmanMr. Matti Esa Manner
Non-Executive DirectorMs. Anne Michelle Clem Whitaker
Non-Executive DirectorMr. Leopoldo Giampaolo Zambeletti
Executive Director, Chief Executive OfficerDr. Markku Tapani Jalkanen
Non-Executive DirectorMr. John Poulos
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2021 Morningstar. All rights reserved.